Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature.
Tumori
; 98(5): 139e-142e, 2012.
Article
en En
| MEDLINE
| ID: mdl-23235770
ABSTRACT
Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Pirroles
/
Encéfalo
/
Carcinoma de Células Renales
/
Inhibidores de la Angiogénesis
/
Síndrome de Leucoencefalopatía Posterior
/
Indoles
/
Neoplasias Renales
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Tumori
Año:
2012
Tipo del documento:
Article
País de afiliación:
Reino Unido